eFFECTOR Therapeutics (EFTR) Stock Price, News & Analysis

Company Overview

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.06
• Volume: 16,276 shs
• Average Volume: 3,176 shs
• Market Capitalization: $940.80
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

eFFECTOR Therapeutics Stock Analysis - MarketRank™

eFFECTOR Therapeutics scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for eFFECTOR Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of eFFECTOR Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of eFFECTOR Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.12% of the outstanding shares of eFFECTOR Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

eFFECTOR Therapeutics has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

eFFECTOR Therapeutics does not currently pay a dividend.

Dividend Growth

eFFECTOR Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.12% of the outstanding shares of eFFECTOR Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

eFFECTOR Therapeutics has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for EFTR on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, eFFECTOR Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.70% of the stock of eFFECTOR Therapeutics is held by insiders.

Percentage Held by Institutions

57.67% of the stock of eFFECTOR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EFTR Stock Analysis - Frequently Asked Questions

How have EFTR shares performed this year?

eFFECTOR Therapeutics' stock was trading at $0.0002 on January 1st, 2025. Since then, EFTR stock has increased by 0.0% and is now trading at $0.0002.

How were eFFECTOR Therapeutics' earnings last quarter?

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) released its quarterly earnings data on Monday, November, 8th. The company reported $10.50 EPS for the quarter, topping analysts' consensus estimates of ($6.50) by $17.00. The firm earned $0.43 million during the quarter.

When did eFFECTOR Therapeutics' stock split?

eFFECTOR Therapeutics shares reverse split before market open on Friday, January 12th 2024.The 1-25 reverse split was announced on Friday, January 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of eFFECTOR Therapeutics?

Shares of EFTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of eFFECTOR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that eFFECTOR Therapeutics investors own include HubSpot (HUBS), Netflix (NFLX), Tesla (TSLA), Athenex (ATNX), ForgeRock (FORG) and Plug Power (PLUG).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 8/08/2025
• Next Earnings (Estimated): 10/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EFTR
• CIK: 1828522
• Web: www.locustwalkacquisitioncorp.com
• Phone: 858-925-8215
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.94) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 4,704,000
• Free Float: 4,483,000
• Market Cap: $940.80
• Optionable: No Data
• Beta: 0.97